BioRepository

APCaRI > Translational Research > BioRepository

Alberta Prostate Cancer Registry & Biorepository

Biorepository

In many instances prostate cancer remains a mystery for researchers. At present, diagnostic tests lack accuracy and there is not a real prognostication tool to differentiate aggressive cancers vs indolent (less aggressive) ones. Thinking is changing in terms of treatment and today more than ever, the clinical and academic research communities need resources to measure outcomes associated with different treatment modalities through comprehensive registries and high quality biospecimens to test new biomarkers that can help better diagnose prostate cancer and predict disease outcomes by establishing biorepositories.

The Alberta Prostate Cancer BioRepository allows APCaRI team members application of state-of-the-art genomic, proteomic, metabolomic and transcriptomic analyses to the development of new and better tests for prostate cancer. Clinical validation of these tests requires large numbers of high quality patient biosamples linked to accurate and complete clinical outcome data.

We offer:

The Alberta Prostate Cancer Biorepository provides biofluid solutions for research. Academic and industry-based researchers worldwide can benefit from biofluids of high quality, diversity and integrity. Five academic teaching hospitals across Alberta currently collect samples and data from participating donors.

Access procedures for researchers are streamlined while ensuring high ethical standards and protection of donor privacy and confidentiality.

APCaRI Biorepository gets certified by CTRNet

Samples Available from participants with prostate cancer and age-matched men with negative biopsy
  • Serum (400uL/vial)
  • Plasma (400uL/vial)
  • Buffy Coat (~300uL/vial)
  • Red Blood Cells (400uL/vial)
  • Urine (400uL/vial)
  • Semen (~400uL/vial)

    Clinical Information

    Clinical registries improve care by arming doctors and teams treating prostate cancer with information about how their outcomes compare with international standards and other locales. The Alberta Prostate Cancer Registry allows us to monitor the patterns of care and outcomes of men diagnosed with prostate cancer throughout Alberta, and provide a valuable tool to track how our translational research efforts are impacting outcomes over time. The registry is linked to a biorepository containing patient specimens that will drive translational research and enable personalized approaches to prostate cancer diagnosis and treatment.

    • Demographic information and co-morbidities
    • Family history of prostate cancer
    • Pathology and diagnosis details
    • Clinical and pathological staging
    • Treatment history
    • Outcomes
    • Biospecimen collection, sample availability and processing details

    The APCaRI Prostate Cancer Registry and Biorepository is a province-wide comprehensive resource that incorporates all prostate cancer patients in Alberta. Biobanking samples from Alberta prostate cancer patients collected through the journey of diagnosis and treatment will translate into enormous benefits because it will lead to tests that are directly applicable to Albertans.

    By the end of 2019 Albertans and the health research community worldwide will have a comprehensive registry and biorepository containing personal, demographic, health and prostate cancer specific information along with biospecimens including blood (serum, plasma, buffy coat, and red blood cells), urine, semen and tissue from close to 9000 patients collected pre-diagnosis and at other multiple time points across the disease continuum.

    In association with the Alberta Cancer Research Biorepository, our biorepository is utilizing cutting edge biobanking technology and supplies to guarantee that we have excellent quality samples managed with the highest standards and that we will have enough samples and data to support research for many years to come.

    You can help us make an impact by donating biospecimens or by supporting our research.

     

     

     

ClarityDX Prostate clinical study expanding to the United States

Oct 8, 2019: APCaRI and Nanostics Inc. are excited to announce the opening of the first recruitment site in the US for the ClarityDX Prostate clinical validation study with Century Clinical Research Inc., based in Daytona Beach, Florida. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer.

The clinical validation study targets the recruitment of 2,800 patients with elevated levels of PSA. Therefore, US recruitment will significantly accelerate the clinical study timeline and increase patient cohort diversity.

Funding support to include US patients comes from the Bird Dogs for Prostate Cancer Research, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University of Alberta. The US and Canadian study samples will continue to be processed in partnership with DynaLIFE Medical Labs in Edmonton, Alberta.

“We’re very happy to partner with Century Clinical Research to recruit US men to our study,” John Lewis, CEO of Nanostics said, “the Florida recruitment site will help us increase the regional diversity of our cohort and strengthen the results of our ClarityDX Prostate study, ultimately, allowing us to make the test available to men across North America.”

“Our extensive clinical trial research experience and diverse patient population in Daytona Beach makes us a perfect partner…” said Thomas Gaskin, Vice-President & CFO of Century Clinical Research, Inc., “we look forward to working with Nanostics to develop their ClarityDX Prostate test to help improve prostate cancer outcomes.”

Implementing ClarityDX Prostate may eliminate up to 600,000 unnecessary biopsies, 24,000 hospitalizations and up to 50% of unnecessary treatments for prostate cancer in North America. This equates to a projected $1.4B per year in cost savings to healthcare and a dramatic impact on the healthcare experience and quality of life for men.

About Century Clinical Research, Inc.
Century Clinical Research, Inc. has over ten years of clinical research experience in multiple specialties, including hematology and oncology. Our staff has completed numerous industry-sponsored clinical trials in phases II-IV and has an excellent track record in quality completion of critical trials. Century Clinical Research, Inc. offers a full research infrastructure and our research staff has been trained in electronic data capture with multiple sponsors. We use a computerized clinical research program for tracking study participation and regulatory documents.
Website: https://www.centuryclinical.com/century_clinical_research.html

- Unknown